Abstract
In this issue of Lung Cancer, two groups report results of phase II clinical trials in malignant mesothelioma, highlighting some of the problems faced by clinical trialists in 2005. Our aims in developing new cancer treatments are to prolong survival and improve symptoms or quality of life as safely and cost-effectively as possible. However, phase II studies cannot tell us if we are achieving these aims. Phase II studies are used to establish anti-tumour efficacy before phase III testing, using surrogate endpoints for patient benefit, most commonly objective response; herein lies the problem.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
